2 days Ago By ABMN Staff
Geode Capital Management LLC trimmed its position in shares of Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ) by 0.4% during the 4th quarter, Holdings Channel.
com reports. The institutional investor owned 472,706 shares of the company’s stock after selling 2,013 shares during the quarter. Geode Capital Management LLC’s holdings in Disc Medicine were worth $29,976,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Disc Medicine by 21.6% in the 3rd quarter.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 18,649 shares of the company’s stock valued at $916,000 after purchasing an additional 3,312 shares during the last quarter. State Street Corp grew its holdings in Disc Medicine by 39.7% during the 3rd quarter.
State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after acquiring an additional 235,115 shares during the last quarter. Barclays PLC increased its position in Disc Medicine by 123.7% in the 3rd quarter.
Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after acquiring an additional 22,202 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in shares of Disc Medicine by 38.7% in the third quarter.
Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock worth $961,000 after acquiring an additional 5,458 shares during the last quarter. Finally, Exome Asset Management LLC lifted its position in shares of Disc Medicine by 5.8% during the third quarter.
Exome Asset Management LLC now owns 64,516 shares of the company’s stock worth $3,170,000 after purchasing an additional 3,516 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.
Disc Medicine Price Performance Shares of Disc Medicine stock opened at $41.00 on Thursday. Disc Medicine, Inc.
has a 1 year low of $25.64 and a 1 year high of $68.73.
The company has a market capitalization of $1.42 billion, a P/E ratio of -10.30 and a beta of 0.
77. The business has a 50-day moving average of $49.99 and a two-hundred day moving average of $55.
31. Insider Buying and Selling In other news, Director Mona Ashiya sold 5,738 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $54.
11, for a total transaction of $310,483.18. Following the completion of the transaction, the director now directly owns 186,541 shares of the company’s stock, valued at $10,093,733.
51. This represents a 2.98 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.
58, for a total value of $87,873.80. Following the transaction, the chief operating officer now owns 40,555 shares of the company’s stock, valued at approximately $2,213,491.
90. The trade was a 3.82 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold a total of 361,690 shares of company stock worth $19,648,094 over the last ninety days. Company insiders own 4.
24% of the company’s stock. Wall Street Analysts Forecast Growth Several research firms have issued reports on IRON. Wedbush reaffirmed an “outperform” rating and set a $90.
00 price objective (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th.
They issued a “buy” rating for the company. Cantor Fitzgerald boosted their price objective on Disc Medicine from $99.00 to $132.
00 and gave the stock an “overweight” rating in a report on Tuesday, March 18th. Stifel Nicolaus lifted their price target on shares of Disc Medicine from $90.00 to $94.
00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Finally, Scotiabank lifted their target price on shares of Disc Medicine from $73.00 to $75.
00 and gave the stock a “sector outperform” rating in a report on Monday, March 3rd. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $93.
80. View Our Latest Analysis on IRON Disc Medicine Profile ( Free Report ) Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Stories Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ).
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
